Citigroup’s Immuneering IMRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$213K Buy
40,417
+2,880
+8% +$14.8K ﹤0.01% 3979
2025
Q4
$247K Buy
37,537
+36,741
+4,616% +$236K ﹤0.01% 3898
2025
Q3
$5.57K Hold
796
﹤0.01% 5205
2025
Q2
$2.68K Hold
796
﹤0.01% 5339
2025
Q1
$1.21K Sell
796
-1,501
-65% -$2.73K ﹤0.01% 5365
2024
Q4
$5.05K Buy
2,297
+1,501
+189% +$3.11K ﹤0.01% 5460
2024
Q3
$1.98K Sell
796
-3,891
-83% -$5.66K ﹤0.01% 5415
2024
Q2
$6K Sell
4,687
-801
-15% -$1.32K ﹤0.01% 5232
2024
Q1
$15.9K Buy
5,488
+1,721
+46% +$9.64K ﹤0.01% 5101
2023
Q4
$27.7K Buy
3,767
+3,078
+447% +$20.5K ﹤0.01% 4848
2023
Q3
$5.29K Sell
689
-5,847
-89% -$53.8K ﹤0.01% 4706
2023
Q2
$66.3K Buy
6,536
+6,236
+2,079% +$60K ﹤0.01% 4475
2023
Q1
$2.91K Sell
300
-103
-26% -$585 ﹤0.01% 5045
2022
Q4
$1.96K Sell
403
-3,806
-90% -$33.7K ﹤0.01% 5246
2022
Q3
$60K Buy
4,209
+3,280
+353% +$26K ﹤0.01% 4307
2022
Q2
$6K Sell
929
-599
-39% -$3.19K ﹤0.01% 5549
2022
Q1
$9K Sell
1,528
-1,430
-48% -$13.7K ﹤0.01% 5576
2021
Q4
$48K Buy
2,958
+1,712
+137% +$41.7K ﹤0.01% 5083
2021
Q3
$33K Buy
+1,246
New +$33.5K ﹤0.01% 4980

Other funds holding IMRX

Citigroup's IMRX Position: Q1 2026 in Review

Citigroup increased its Immuneering (IMRX) stake by 7.7% in Q1 2026, buying an estimated $14.8K and bringing the position to 40,417 shares worth $213K. The position accounts for ﹤0.01% of the portfolio, ranked #3979.

Citigroup first reported a position in IMRX in Q3 2021 and has held it in 19 quarters since. The position peaked at $247K in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Citigroup held 40,417 shares of Immuneering worth $213K as of Q1 2026.
  • Citigroup bought 2,880 Immuneering shares in Q1 2026, an estimated $14.8K.
  • Immuneering made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3979 holding.
  • Citigroup first reported a position in Immuneering in Q3 2021 and has held it in 19 quarters since.
  • Citigroup's Immuneering position peaked at $247K in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.